By means of unbiased approaches, we demonstrate for the first time for any FGFR2 fusion-positive solid tumor, and specifically for ICC, that combined FGFR and HDAC inhibition is synergistic in these clinically relevant models. Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.